ICU antibiotic dosing under the microscope: new study targets dialysis clearance
NCT ID NCT07167524
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how the antibiotics piperacillin and tazobactam are cleared from the body by continuous kidney replacement therapy in intensive care patients with severe infections. Researchers will measure drug levels in 24 adults to better understand dosing needs. The goal is to improve treatment effectiveness and reduce risks like underdosing or toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
piperacillin and tazobactam (antibiotics)
What this could lead to
If successful, this could help doctors determine the right antibiotic doses for ICU patients on kidney dialysis, potentially improving treatment and reducing side effects.
What could go wrong
This is a small, early observational study with only 24 participants. It does not test a new treatment, so it may not lead to immediate changes in patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Rouen Hospital
Rouen, 76031, France
Contact Phone: •••-•••-•••• Email: •••••@•••••